Hydroxysafflor Yellow A Improves Established Monocrotaline-induced Pulmonary Arterial Hypertension in Rats

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2016 Apr 10

PMID 27059291

Citations 6

Authors

Xiaotong Han

Yixiong Zhang

Zhou Zhou

Xingwen Zhang

Yanfei Long

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the beneficial effects of hydroxysafflor yellow A (HSYA) on monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rats, and to investigate the main pathophysiological mechanism of HSYA in preventing development of MCT-induced PAH.

Methods: Four groups (control, control with HSYA treatment, MCT-exposed, and MCT-exposed with HSYA treatment) were evaluated at day 28 following MCT exposure. Haemodynamic measurements, right ventricular hypertrophy, morphometry, inflammatory cytokines and oxidant expression were assessed.

Results: HSYA significantly reduced haemodynamic changes, right ventricular hypertrophy and morphometric changes induced by exposure to MCT. HYSA also suppressed MCT-induced inflammation and oxidative stress in rat pulmonary tissue.

Conclusions: Experimental MCT-induced PAH may be reduced by HSYA treatment, and the mechanism may involve suppression of inflammation and oxidative stress.

Citing Articles

Investigating the therapeutic effects and mechanisms of Carthamus tinctorius L.-derived nanovesicles in atherosclerosis treatment.

Yang R, Lin F, Wang W, Dai G, Ke X, Wu G Cell Commun Signal. 2024; 22(1):178.

PMID: 38475787 PMC: 10936069. DOI: 10.1186/s12964-024-01561-6.

Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension.

Ji X, Lei C, Kong S, Li H, Pan S, Chen Y Drug Des Devel Ther. 2024; 18:475-491.

PMID: 38405578 PMC: 10893878. DOI: 10.2147/DDDT.S439686.

Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.

Xue Z, Li Y, Zhou M, Liu Z, Fan G, Wang X Front Pharmacol. 2021; 12:720873.

PMID: 34899290 PMC: 8660120. DOI: 10.3389/fphar.2021.720873.

Inhibitory effects of formononetin on the monocrotaline‑induced pulmonary arterial hypertension in rats.

Wu Y, Cai C, Yang L, Xiang Y, Zhao H, Zeng C Mol Med Rep. 2020; 21(3):1192-1200.

PMID: 31922224 PMC: 7003019. DOI: 10.3892/mmr.2020.10911.

The Effects of Safflower Yellow on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Clinical Trial.

Li X, Kang Y, Wang R, Liao X, Ou X, Liu J Evid Based Complement Alternat Med. 2019; 2019:5952742.

PMID: 30728848 PMC: 6341243. DOI: 10.1155/2019/5952742.

References

Wang Q, Zuo X, Wang Y, Xie W, Wang H, Zhang M . Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats. Vascul Pharmacol. 2012; 58(1-2):71-7. DOI: 10.1016/j.vph.2012.07.006. View

Niimi K, Yasui T, Hirose M, Hamamoto S, Itoh Y, Okada A . Mitochondrial permeability transition pore opening induces the initial process of renal calcium crystallization. Free Radic Biol Med. 2012; 52(7):1207-17. DOI: 10.1016/j.freeradbiomed.2012.01.005. View

Kolli M, Manne N, Para R, Nalabotu S, Nandyala G, Shokuhfar T . Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension. Biomaterials. 2014; 35(37):9951-9962. PMC: 4758344. DOI: 10.1016/j.biomaterials.2014.08.037. View

Sun X, Wei X, Qu S, Zhao Y, Zhang X . Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats. Bioorg Med Chem Lett. 2010; 20(14):4120-4. DOI: 10.1016/j.bmcl.2010.05.076. View

Fan Y, Zhang R, Jiang X, Wen L, Wu D, Liu D . The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovasc Res. 2013; 99(3):395-403. DOI: 10.1093/cvr/cvt109. View

Lawrie A, Hameed A, Chamberlain J, Arnold N, Kennerley A, Hopkinson K . Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am J Pathol. 2011; 179(4):1693-705. PMC: 3181351. DOI: 10.1016/j.ajpath.2011.06.037. View

Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes K, Lopaschuk G . Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010; 2(44):44ra58. DOI: 10.1126/scitranslmed.3001327. View

Xu D, Guo H, Xu X, Lu Z, Fassett J, Hu X . Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase. Hypertension. 2011; 58(2):303-9. PMC: 3170043. DOI: 10.1161/HYPERTENSIONAHA.110.166819. View

Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber L . Inflammatory cytokines in pulmonary hypertension. Respir Res. 2014; 15:47. PMC: 4002553. DOI: 10.1186/1465-9921-15-47. View

10.

Del Rio D, Stewart A, Pellegrini N . A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005; 15(4):316-28. DOI: 10.1016/j.numecd.2005.05.003. View

11.

Galie N, Manes A . New treatment strategies for pulmonary arterial hypertension: hopes or hypes?. J Am Coll Cardiol. 2013; 62(12):1101-1102. DOI: 10.1016/j.jacc.2013.06.032. View

12.

Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L . The role of oxidative stress during inflammatory processes. Biol Chem. 2013; 395(2):203-30. DOI: 10.1515/hsz-2013-0241. View

13.

Han S, Li H, Ma X, Zhang K, Ma Z, Tu P . Protective effects of purified safflower extract on myocardial ischemia in vivo and in vitro. Phytomedicine. 2009; 16(8):694-702. DOI: 10.1016/j.phymed.2009.02.019. View

14.

Richards G, White H, Grimmer H, Ramoroka C, Channa K, Hopley M . Increased oxidants and reduced antioxidants in irradiated parenteral nutrition solutions may contribute to the inflammatory response. J Intensive Care Med. 2009; 24(4):252-60. DOI: 10.1177/0885066609332744. View

15.

Kong D, Xia W, Zhang Z, Xiao L, Yuan D, Liu Y . Safflower yellow injection combined with conventional therapy in treating unstable angina pectoris: a meta-analysis. J Tradit Chin Med. 2014; 33(5):553-61. DOI: 10.1016/s0254-6272(14)60021-2. View

16.

Luan Y, Chao S, Ju Z, Wang J, Xue X, Qi T . Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response. Int Immunopharmacol. 2015; 26(1):188-93. DOI: 10.1016/j.intimp.2015.01.009. View

17.

Wu Y, Wang L, Jin M, Zang B . Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury. Biol Pharm Bull. 2012; 35(4):515-22. DOI: 10.1248/bpb.35.515. View

18.

Ahmed L, Obaid A, Zaki H, Agha A . Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol. 2014; 740:379-87. DOI: 10.1016/j.ejphar.2014.07.026. View

19.

Li X, Huang C, Zhang T, Teper A, Srivastava K, Schofield B . The chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates TH1/TH2 responses in a murine model of allergic asthma. J Allergy Clin Immunol. 2000; 106(4):660-8. DOI: 10.1067/mai.2000.110102. View

20.

Sun C, Pei C, Zang B, Wang L, Jin M . The ability of hydroxysafflor yellow a to attenuate lipopolysaccharide-induced pulmonary inflammatory injury in mice. Phytother Res. 2010; 24(12):1788-95. DOI: 10.1002/ptr.3166. View